CHONGQING, CHINA - APRIL 23: In this photo illustration, the logo of Pfizer Inc. is displayed on a smartphone screen, with a stock market chart visible in the background, reflecting trading activity ...

The payout ratio is over 100% for this high-yield healthcare giant, but don't run for the hills just yet.

Pfizer's vaccine business cooled off, and it is on its back foot in the GLP-1 race, but don't count the drug giant out.

Pfizer (NYSE: PFE) has been around for over 175 years, but it became a true household name during the COVID-19 pandemic as one of the main vaccine suppliers. That led to its stock price and revenue ...

Pfizer has a long history of success in the competitive and complex drug sector. The pharmaceutical giant has patent expirations coming in 2027 and 2028. Management's attempt to solve the issue has ...

It is also highly likely to be an important player in the industry where it competes. But that doesn't seem to matter today ...

Pfizer (PFE) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the near ...

Pfizer (PFE) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the near ...

FDA approves VEPPANU (vepdegestrant), the first PROTAC protein degrader therapy, for ER+/HER2-, ESR1-mutated advanced breast cancer. Pfizer and Arvinas co developed VEPPANU, targeting patients who ...